STOCK TITAN

Athersys Inc - ATHX STOCK NEWS

Welcome to our dedicated news page for Athersys (Ticker: ATHX), a resource for investors and traders seeking the latest updates and insights on Athersys.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Athersys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Athersys's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.82%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.38%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.54%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.94%
Tags
management
Athersys Inc

Nasdaq:ATHX

ATHX Rankings

ATHX Stock Data

833.20k
61.15M
0.77%
4.42%
3.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cleveland

About ATHX

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.